Medicus Pharma Ltd 2025年季度报告

For the quarterly period endedMarch 31, 2025OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___to ___ Commission file number:001-42408MEDICUS PHARMA LTD. (Exact Name of Registrant as Specified in Its Charter) Ontario, Canada incorporation or organization)300 Conshohocken State Rd., Suite 200W. Conshohocken,PA (Address of principal executive offices) (610)636-0184(Registrant's telephone number, including area code) Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days. Condensed Consolidated Balance Sheets as of March 31, 2025 (Unaudited) and December 31, 2024Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2025 and 2024 (Unaudited)Condensed Consolidated Statements of Changes in Shareholders' Equity for the three months ended March 31, 2025and 2024 (Unaudited)Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2025 and 2024(Unaudited)Notes to Condensed Consolidated Financial Statements (Unaudited)Management's Discussion and Analysis of Financial Condition and Results of OperationsQuantitative and Qualitative Disclosures Regarding Market RiskControls and Procedures Mine Safety Disclosures Report on Form 10-Q regarding our strategy, future operations, future financial position, projected costs, prospects, plans, andobjectives of management are forward-looking statements. These statements involve known and unknown risks, uncertainties, andother important factors that may cause our actual results, performance, or achievements to be materially different from any futureresults, performance, or achievements expressed or implied by the forward-looking statements. The words "anticipate," "believe," Research and developmentTotal operating expenses SharesAmountcapitaldeficitBalance as of December 31, 202411,816,721$30,518,195$1,520,412$(28,903,903)$3,134,704Issuance of common shares and warrants in connection with Issuance of common shares in connection with SEPAoffering costs Issuance of common shares upon exercise of stock warrants5,00014,000--Stock-based compensation--112,277-Net loss and comprehensive loss for the period---(5,102,408)(5,102,40 Balance as of March 31, 20251$32,908,702$3,245,163$11)$2,147,554 SharesAmountcapitaldeficit8,076,673$18,761,25(17,748,3 Stock-based compensation--35,953-Net loss and comprehensive loss for the period---(1,707,358)(1,707,35Balance as of March 31, 20248,076,673$18,761,250$134,538$(19,455,745)$(559,957)The accompanying notes are an integral part of the unaudited condensed consolidated financial statements. Cash flows from operating activities:Net loss for the period$(5,102,408)$(1,707,358)Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense112,277Change in operating lease right-of-use assets23,480Changes in operating assets and liabilities:Prepaid expenses122,639Accounts payable655,634364,275 Cash paid for financing costs in connection with SEPANet cash provided by financing activities Net decrease in cash and cash equivalents during the period(181,893)(1,176,933)Cash and cash equivalents, beginning of the year4,164,3231,719,338Cash and cash equivalents, end of the year$3,982,430$Supplemental disclosure of non-cash investing and financing activitiesRight-of-use assets obtained in exchange for lease liabilities$-$ Medicus Pharma Ltd. (the "Company" or "Medicus Pharma"), formerly Interactive Capital Partners Corporation ("Interactive"), is aclinical stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.The Company is a public limited Company originally incorporated pursuant to the provisions of the Business Corporations Act(Ontario) on April 30, 2008, as a private company named Interactive Capital Partners Corporation, with nominal assets and liabilities.The Company's registered office is located at 100 King Street West, Suite 3400, One First Canadian Place, Toronto, Ontario, Canada. through equity and debt financings. On February 10, 2025, the Company announced that it had entered into the SEPA (as defined below). Subject to the satisfaction ofcertain conditions, Yorkville (as defined below) has committed to purchase the Company's common shares up to an aggregate grosssales price of $15,000,000during the 36 months following the date of the SEPA. See Note 6 for further details. Company issued1,490,000units at a price of $2.80per unit.Each unit consists of one common share of the Company and onewarrant to purchase one common share. The Company expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. Inad